Genital Herpes and the Teen Female

Journal of Pediatric and Adolescent Gynecology

Volumn 20, Issue 6, 2007, Pages 319-321

  Batalden, Karin ^a   Bria, Corinne ^a   Biro, Frank M ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; HERPES SIMPLEX VIRUS 1 ANTIBODY; HERPES SIMPLEX VIRUS 2 ANTIBODY; UNCLASSIFIED DRUG; VALACICLOVIR; VIRUS ANTIBODY;

ADOLESCENCE; ANTIVIRAL THERAPY; CLINICAL TRIAL; EDITORIAL; ETHNICITY; GENDER; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RACE; SCREENING TEST; SEROLOGY; SEROPREVALENCE; UNITED STATES; VIRUS TRANSMISSION;

ADOLESCENT; ANTIVIRAL AGENTS; FEMALE; HERPES GENITALIS; HUMANS;

EID: 36849042070     PISSN: 10833188     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpag.2007.04.004     Document Type: Editorial

References (23)

1. Xu F., Sternberg M.R., Kottiri B.J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296 (2006) 964
2. Stanberry L.R., Rosenthal S.L., Mills L., et al. Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin Infect Dis 39 (2004) 1433
3. Beauman J.G. Genital herpes: A review. Am Fam Physician 72 (2005) 1527
4. Xu F., Schillinger J.A., Sternberg M.R., et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis 185 (2002) 1019
5. CDC. Sexually Transmitted Diseases Treatment Guidelines. MMWR 2006 (2006) 55 (RR11)
6. Brown Z.A., Selke S., Zeh J., et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 337 (1997) 509
7. Carney O., Ross E., Bunker C., et al. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med 70 (Feb 1994) 40
8. Taboulet F., Halioua B., and Malkin J.E. Quality of life and use of health care among people with genital herpes in France. Acta Derm Venereol 79 (1999) 380
9. Corey L., Wald A., Patel R., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 350 (2004) 11
10. Fife K.H., Warren T.J., Ferrera R.D., et al. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: A US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 81 (2006) 1321
11. Diaz-Mitoma F., Sibbald R.G., Shafran S.D., et al. Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. J Adolesc Health Care 280 (1998) 887
12. Patel R., Bodsworth N.J., Woolley P., et al. Valaciclovir for the suppression of recurrent genital HSV infection: A placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Genitourin Med 73 (1997) 105
13. Patel R., Tyring S., Strand A., et al. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Inf 75 (1999) 398
14. Williams J.R., Jordan J.C., Davis E.A., et al. Suppressive valacyclovir therapy: Impact on the population spread of HSV-2 infection. Sex Transm Dis 34 (2007) 123
15. Tyring S.K., Baker D., and Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 186 Suppl. 1 (2002) S40
16. Honda M., Okuda T., Hasegawa T., et al. Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir resistance of herpes simplex virus type 2. Antivir Chem Chemother 12 (Jul 2001) 233
17. Aoki F.Y., Tyring S., Diaz-Mitoma F., et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: A randomized, double-blind, placebo-controlled trial. Clin Infect Dis 42 (2006) 8
18. Bodsworth N.J., Crooks R.J., Borelli S., et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med 73 (Apr 1997) 110
19. Chosidow O., Drouault Y., Leconte-Veyriac F., et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol 144 (Apr 2001) 818
20. Leone P.A., Trottier S., and Miller J.M. Valacyclovir for episodic treatment of genital herpes: A shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 34 (2002) 958
21. Wald A., Carrell D., Remington M., et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 34 (2002) 944
22. Sheffield J.S., Hollier L.M., Hill J.B., et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: A systematic review. Obstet Gynecol 102 (2003) 1396
23. Sheffield J.S., Hill J.B., Hollie L.M., et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: A randomized clinical trial. Obstet Gynecol 108 (2006) 141